The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

MF-tricyclic     3-(3,4-difluorophenyl)-4-(4...

Synonyms: MF Tricyclic, CHEMBL18264, AG-E-11766, SureCN2159864, CHEBI:121704, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MF Tricyclic


High impact information on MF Tricyclic

  • RESULTS: MF-Tricyclic and Sulindac reduced the relative risk of development of esophageal cancer by 55% (95% confidence interval [CI] = 43%-66%, P < 0.008) and by 79% (95% CI = 68%-87%, P < 0.001), respectively, compared with controls [1].
  • A selective COX-2 inhibitor was administered either acutely [NS398; 100 mg/kg, i.p.] on day 14 or chronically in chow [MF. tricyclic; 0.015%, p.o.] from day 6 to day 14 after tumor implantation [5].
  • Apc+/-Msh2-/- mice treated with MF-tricyclic had significantly fewer small-bowel polyps (mean +/- SD, 178 +/- 29) compared with mice on sulindac (278 +/- 80), or control diet (341 +/- 43; P < 0.001) [2].
  • Both MF-tricyclic and sulindac further increased blood pressure and albuminuria in mREN2 rats [6].
  • Renal effects of a selective cyclooxygenase-2 (COX-2) inhibitor [MF-Tricyclic; 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone] were studied in control and volume-depleted conscious dogs [7].

Associations of MF Tricyclic with other chemical compounds


Analytical, diagnostic and therapeutic context of MF Tricyclic

  • RESULTS: In vivo COX-2 inhibition, unexpectedly increased viral load: in the CMV-infected animals viral load was 2.58 +/- 1.0 in the nontreated group, 4.74 +/- 1.38 in the group treated with 12 mg/kg/day MF-tricyclic, and 6.51 +/- 1.64 in the group treated with 24 mg/kg/day MF-tricyclic (p trend = 0.050) [3].


  1. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Buttar, N.S., Wang, K.K., Leontovich, O., Westcott, J.Y., Pacifico, R.J., Anderson, M.A., Krishnadath, K.K., Lutzke, L.S., Burgart, L.J. Gastroenterology (2002) [Pubmed]
  2. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Lal, G., Ash, C., Hay, K., Redston, M., Kwong, E., Hancock, B., Mak, T., Kargman, S., Evans, J.F., Gallinger, S. Cancer Res. (2001) [Pubmed]
  3. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. Rott, D., Zhu, J., Burnett, M.S., Zhou, Y.F., Zalles-Ganley, A., Ogunmakinwa, J., Epstein, S.E. J. Am. Coll. Cardiol. (2003) [Pubmed]
  4. MF tricyclic and sulindac retard tumor formation in an animal model. Dvory-Sobol, H., Kazanov, D., Liberman, E., Birkenfeld, S., Bulvik, B., Luk, P., Leshno, M., Arber, N. Int. J. Cancer (2006) [Pubmed]
  5. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Sabino, M.A., Ghilardi, J.R., Jongen, J.L., Keyser, C.P., Luger, N.M., Mach, D.B., Peters, C.M., Rogers, S.D., Schwei, M.J., de Felipe, C., Mantyh, P.W. Cancer Res. (2002) [Pubmed]
  6. Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27). Cheng, Z.J., Finckenberg, P., Louhelainen, M., Merasto, S., Tikkanen, I., Vapaatalo, H., Mervaala, E.M. Eur. J. Pharmacol. (2003) [Pubmed]
  7. Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs. Black, S.C., Brideau, C., Cirino, M., Belley, M., Bosquet, J., Chan, C.C., Rodger, I.W. J. Cardiovasc. Pharmacol. (1998) [Pubmed]
WikiGenes - Universities